Immune Checkpoint Inhibitors in Oncology: Nivolumab (Opdivo)

nivolumab (Opdivo) injection oncology cancer

Tumour cells harness multiple resistance mechanisms to evade the host-tumour immune system. Notably, the programmed death 1 (PD1) receptor and its ligands, PD-L1 and PD-L2, play critical roles in T-cell suppression and exhaustion. Overexpression of PD-L1 and PD1 on tumour cells and tumour-infiltrating lymphocytes . . .

Sign Up or Log In as a healthcare professional to read the full article.

Share via

Also worth reading


Behçet’s Disease: 1 out of 25000 people in Japan

Behçet’s disease is a rare autoimmune condition that affects various parts of the body, including the eyes, mouth, genitals, and skin. The disease is most prevalent in Turkey and the Middle East, while data is available in China and Japan. Here’s everything you need to know about Behçet’s disease.

Read More »

People also read: